Rifabutin and sparfloxacin but not azithromycin inhibit binding of Mycobacterium avium complex to HT-29 intestinal mucosal cells
- 1 May 1994
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 38 (5) , 1200-1202
- https://doi.org/10.1128/aac.38.5.1200
Abstract
Organisms of the Mycobacterium avium complex (MAC) cause disseminated disease in patients with AIDS, and evidence points to the gastrointestinal tract as the major route of infection. Since MAC can bind to and invade intestinal mucosal cells, we examined whether subinhibitory concentrations of antibiotics which have anti-MAC activity in vitro affect the interaction between MAC and HT-29 intestinal mucosal cells. MAC isolates were exposed to subinhibitory concentrations of rifabutin (MIC, 2.6 micrograms/ml), sparfloxacin (MIC, 8.4 micrograms/ml), or azithromycin (MIC, 32 micrograms/ml) for 30 to 120 min, washed, and incubated with HT-29 cell monolayers for 2 h at 4 degrees C. HT-29 cell monolayers were then washed to remove unbound bacteria and were subsequently lysed. The number of MAC isolates that bound to the HT-29 cells was determined by plating the cell lysate onto 7H10 agar. Preincubation of the MAC isolates with rifabutin at concentrations of 1 and 2 micrograms/ml reduced MAC binding to HT-29 cells by 80 to 90%, while MAC exposed to sparfloxacin at 1 and 7 micrograms/ml inhibited binding by 77 to 93%. Azithromycin at concentrations of 2, 10, and 30 micrograms/ml had no effect on MAC binding to HT-29 cells. Inhibition of MAC binding to the gastrointestinal mucosa may be one underlying mechanism for the prophylactic effects of rifabutin and quinolones.Keywords
This publication has 15 references indexed in Scilit:
- Two Controlled Trials of Rifabutin Prophylaxis against Mycobacterium avium Complex Infection in AIDSNew England Journal of Medicine, 1993
- Incidence of Mycobacterium avium-intracellulare Complex Bacteremia in Human Immunodeficiency Virus-Positive PatientsThe Journal of Infectious Diseases, 1992
- Azithromycin for treatment of Mycobacterium avium-intracellulare complex infection in patients with AIDSThe Lancet, 1991
- Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophagesAntimicrobial Agents and Chemotherapy, 1991
- Mycobacterium aviumComplex Infection in the Acquired Immunodeficiency SyndromeNew England Journal of Medicine, 1991
- Effect of rifabutin on disseminated Mycobacterium avium infections in thymectomized, CD4 T-cell-deficient miceAntimicrobial Agents and Chemotherapy, 1990
- In vivo activity of amikacin alone or in combination with clofazimine or rifabutin or both against acute experimental Mycobacterium avium complex infections in beige miceAntimicrobial Agents and Chemotherapy, 1988
- Determination of in vitro susceptibility of Mycobacterium avium complex isolates to antimycobacterial agents by various methodsAntimicrobial Agents and Chemotherapy, 1987
- Mycobacterial Infections in. AIDS Patients, with an Emphasis on the Mycobacterium avium ComplexClinical Infectious Diseases, 1986
- A single genetic locus encoded by Yersinia pseudotuberculosis permits invasion of cultured animal cells by Escherichia coli K-12Nature, 1985